ORPHELIA Pharma announces the granting of the Marketing Authorisation for Ivozall® from the European Commission UncategorizedBy Charlotte Maddalena25 November 2019
Preclinical data of novel ICI combination with anti-PD1 or anti-CTLA4 therapies UncategorizedBy Charlotte Maddalena7 November 2019
